We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Meridian Acquires Euprotein to Further Expand Recombinant Protein Capabilities

By LabMedica International staff writers
Posted on 03 May 2022
Image: EUPROTEIN offers custom development and production of bioresearch reagents (Photo courtesy of EUPROTEIN)
Image: EUPROTEIN offers custom development and production of bioresearch reagents (Photo courtesy of EUPROTEIN)

Meridian Bioscience, Inc. (Cincinnati, OH, USA) has acquired, through its subsidiary Meridian Life Science, Inc., substantially all of the assets of EUPROTEIN Inc. (North Brunswick Township, NJ, USA).

EUPROTEIN offers custom development and production of high-quality bioresearch reagents, with a particular focus on human and other mammalian proteins and recombinant monoclonal antibodies. The acquisition will help Meridian accelerate its pipeline of new immunological reagents while expanding recombinant capabilities.

"We are excited to welcome EUPROTEIN into the Meridian family," said Jack Kenny, Meridian Bioscience Chief Executive Officer. "We already extensively work with EUPROTEIN on projects with our Life Science R&D team, and they are well-positioned to help us accelerate our pipeline of new immunological reagents."

"The EUPROTEIN team is delighted to join Meridian," added Guangli Wang, Ph.D., Founder, and CEO of EUPROTEIN. "Combining our products and capabilities with Meridian's global reach and stellar reputation for providing the highest quality reagents furthers our vision of making a lasting impact on global healthcare."

Related Links:
Meridian Bioscience, Inc. 
EUPROTEIN Inc.

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Clinical Informatics Platform
CLARION™
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group

Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
INTEGRA BIOSCIENCES AG